Detalles de la búsqueda
1.
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Int J Mol Sci
; 21(15)2020 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32707880
2.
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Mult Scler
; 24(14): 1862-1870, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30415593
3.
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
BMC Neurol
; 17(1): 29, 2017 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183276
4.
Impact of Cognitive Impairment on Adults with Multiple Sclerosis and Their Family Caregivers.
Int J MS Care
; 23(3): 93-100, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34177380
5.
A feasibility study of a manualized resilience-based telehealth program for persons with multiple sclerosis and their support partners.
Mult Scler J Exp Transl Clin
; 6(3): 2055217320941250, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32913660
6.
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
J Neurol
; 266(5): 1182-1193, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30820738
Resultados
1 -
6
de 6
1
Próxima >
>>